Pharma Industry
Pharma Industry 12/03/2010
Time for drug giants to jump into the patent pool?
A patent pool is a virtual concept, involving patent-holding drug companies allowing anybody to make cheap copies of their drugs or - importantly - combine the drugs of several different big R&D companies in a single pill for adults or children.
Pharma Industry 09/03/2010
Germany "to break pharma price monopoly"
German Health Minister is expected to announce plans to reform the branded pharmaceutical market, including a requirement that drugmakers must negotiate prices for their new drugs with the public health insurers, or accept fixed price ceilings if they fail to reach agreement.
Pharma Industry 08/03/2010
Generics set to pummel Belgian pharma market growth
The branded medicines “patent cliff” will slow growth in Belgium’s pharmaceutical market to an average of just 0.46% each year to 2014, in local currency terms, down from the 3.4% average annual increases reported for 2004-9, say new forecasts.
Pharma Industry 04/03/2010
Personalized medicine could shake up drug industry
As the number of prospective "blockbuster" drugs has dwindled, drug manufacturers are increasingly exploring treatments targeted to smaller patient populations based on genetic testing, as genomic testing can help doctors pick the best treatment with less guesswork. Personalized medicine can lower the overall cost of patient care.
Pharma Industry 04/03/2010
Bristol-Myers Squibb discusses pipeline with investors
The company has particularly high hopes for investigative compounds to treat Alzheimer’s disease and hepatitis C.
Pharma Industry 03/03/2010
PhRMA pushes for data exclusivity in 2010 Special 301 comments
PhRMA 2010 Special 301 submission systematically lists in great detail, grievances against 41 countries for, in its view, the insufficient implementation and enforcement of national IP legislation.
Pharma Industry 03/03/2010
GeoVax Labs, Inc. reports fourth quarter and year end 2009 financial results
Submits therapeutic vaccine IND and awaits FDA response.
Pharma Industry 03/03/2010
Merck announces robust integrated pipeline with more than 20 medicines and vaccines in late-stage development
Integrated pipeline includes potential first-in-class candidates in therapeutic areas including cardiology, diabetes and infectious disease.
Pharma Industry 26/02/2010
Thai govt policies are killing local pharma, says industry
Drugmakers in Thailand have urged the government to revoke the “special privileges” granted to the Government Pharmaceutical Organisation (GPO), claiming that these are unfair and destroying the domestic commercial industry.
Pharma Industry 18/02/2010
Drug firms apply brand to generics
Some prestigious brand-name pharmaceutical companies that once looked askance at the high-volume, low-cost business of generic drugs are now becoming major purveyors of generic medicines.
Pharma Industry 17/02/2010
Biotech marathon: Vaccines and open innovation, but less IP?
Intellectual property seems to be at a crossroads where industry still strongly favours it but some speakers voiced concerns about the possible counter-effects of too much IP protection on innovation.
Pharma Industry 13/02/2010
Indian pharma net profits “to soar 50%+ this year”
Net profits at 25 leading Indian drugmakers are set to soar more than 50% this year, while their consolidated revenues will increase 10%-14%, according to a new analysis.
Pharma Industry 11/02/2010
Pharma needs to work with non-traditional partners to survive
Pharmaceutical companies should be working with IT companies, mobile phone firms and other non-traditional healthcare firms if they are to successfully make the switch from being product-focused to customer-centric, claims a new report from Ernst & Young.
Pharma Industry 10/02/2010
Gilead Quad pill may overtake Atripla, Milligan says
Gilead will begin three final-stage tests in 2010 for a four-drug combination pill against HIV that has the potential to generate $4 billion a year by 2014.
Pharma Industry 10/02/2010
Cost-cutting and emerging markets key for Europe's drugmakers
Now that four of the six European pharma majors have reported their fourth quarter and full-year financials, cost-cutting and emerging market growth are the two striking areas, according to analysts at Collins Stewart.
Pharma Industry 01/02/2010
Drug patent regime has led to high prices: US Study
Other reasons include transfer of marketing rights to larger companies and mergers and acquisitions among drug companies.
Pharma Industry 01/02/2010
B-MS looking at acquisitions and definitely 'not for sale'
Sales of the Sustiva franchise rose 19% to $358 million, and Reyataz was up 18% to $388 million. Revenues from Baraclude for hepatitis B climbed 39% to $212 million.
Pharma Industry 28/01/2010
Gilead Sciences reviewing Notice Letter regarding Teva Pharmaceuticals' generic Viread ANDA
Viread is currently protected by four patents, which are listed in the FDA’s Approved Drug Products List, and all four patents would need to be invalidated or expired before a generic version of Viread could be marketed.
Pharma Industry 28/01/2010
Gilead profit rises on sales of AIDS pills, flu drug
Gilead Sciences Inc. said fourth-quarter profit jumped 43 percent on demand for AIDS drugs and surging royalties from the anti-flu treatment Tamiflu.
Pharma Industry 18/01/2010
Obama battles Congress and PhRMA over biogenerics
US research-based drugmakers have threatened to withdraw their support for President Barack Obama’s health care reforms unless biologic drugs receive 12 years’ guaranteed protection from generic competition.
More...
